Achieve Life Sciences, Inc.
QUIT Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Nov 9, 2026
$6.78
Latest quarter · Q3 '26 results quarter ended Sep 30, 2026 · vs Q3 '25
| Line | Q3 '25 | Q3 '26 | Change (y/y) |
|---|---|---|---|
| Net income | −$14.4M | −$12.1M | — |
| Diluted EPS | −$0.28 | −$0.11 | — |
| Free cash flow | — | −$8.4M | — |
Fiscal 2026 so far (3 quarters) vs a year earlier
| Net income | −$97.0M | |
| Diluted EPS | −$1.10 |
Key numbers, fiscal 2025
Market cap
$715M
P/E
—
Revenue
—
Net income
−$54.6M
Free cash flow
−$49.5M
Operating margin
—
Achieve Life Sciences, Inc. in 30 seconds fiscal 2025
Does it make a profit?
−$54.6M
No. It lost money last year.
How long would its cash last?
4.6 yrs
Comfortably. It burns $44.1M a year and holds $202M, about 4.6 years at that pace.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Achieve Life Sciences, Inc. does
Achieve Life Sciences develops cytisinicline, a drug candidate intended to help people stop smoking cigarettes or using nicotine e-cigarettes. Cytisinicline is a naturally occurring substance that acts on nicotine receptors in the brain and is intended to reduce cravings and withdrawal symptoms. The company has developed a 3 mg tablet and treatment schedules of 6 or 12 weeks. The product is investigational and has not been approved by the FDA in the United States. Achieve focuses on developing cytisinicline for smoking cessation and vaping cessation, with the goal of seeking approval in the United States and other markets. It holds an exclusive license and supply agreement with Sopharma to develop and commercialize the drug outside Sopharma’s territories, which are mainly in Central and Eastern Europe and also include Scandinavia, North Africa, the Middle East, Central Asia and Vietnam. Sopharma has marketed a cytisinicline product in its territories for over 20 years.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- ACHIEVE LIFE SCIENCES, INC.
- CIK
- 0000949858
Achieve Life Sciences, Inc. · QUIT · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$33.2M | −$42.4M | −$29.8M | −$39.8M | −$54.6M |
| Diluted EPS | −$4.08 | −$4.00 | −$1.50 | −$1.24 | −$1.25 |
| Cash | |||||
| Cash from operations | −$29.4M | −$37.6M | −$24.5M | −$29.8M | −$49.5M |
| Capital expenditure | — | — | $0.0M | — | $0.0M |
| Free cash flow | — | — | −$24.5M | — | −$49.5M |
| Share count change | 198.6% | 30.5% | 87.2% | 61.8% | 35.9% |
| Debt and strength | |||||
| Cash and short-term investments | $43.0M | $24.8M | $15.5M | $34.4M | $36.4M |
| Shareholders' equity | $28.0M | $8.3M | −$1.4M | $20.9M | $21.5M |
| Current ratio | 9.8x | 1.3x | 0.8x | 5.5x | 4.4x |
| Returns and quality | |||||
| Return on equity | −101.5% | −233.0% | −869.9% | −409.5% | −257.7% |
| Return on tangible equity | −130.7% | −723.8% | — | −210.8% | −276.9% |
Insider trades 12 months
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.2M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Achieve Life Sciences, Inc. · QUIT · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0000949858). Latest version: stoqly.net/companies/quit. Data updated November 11, 2026. For information only — not investment advice. Check the original filings before relying on any figure.